Âé¶¹´«Ã½Ó³»­

Âé¶¹´«Ã½Ó³»­

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Intravenous Immunoglobulin Use in West Nile Encephalitis: A report of two cases.
Infectious Disease
Infectious Disease Posters (7:00 AM-5:00 PM)
023

To describe vignettes of neuroinvasive West Nile associated disease (N-WNAD) successfully treated with intravenous immunoglobulin (IVIG).

Most West Nile virus (WNV) infections are asymptomatic. However, 1% of infected individuals develop N-WNAD including meningitis, encephalitis, and acute flaccid paralysis. Overall case fatality is 5-10%. While supportive care is considered the current standard of care, earlier studies suggested a possible role for IVIG.

Case series and literature review.

Patient-1, A young man in his twenties developed headaches, severe cognitive and memory alterations, and opsoclonus myoclonus after spending time in Wisconsin. IgM antibodies were detected in spinal fluid and serum against WNV. MRI brain was unrevealing. Timely IVIG and dexamethasone administration resulted in progressive improvement. Six months later, he had complete resolution of all neurological symptoms.  Patient-2, An older man in his eighties developed fever, disorientation, and vomiting after spending time in Michigan. IgM antibodies were detected in spinal fluid and serum against WNV. MRI brain showed bilateral T2-hyperintensity in temporal lobes. Mentation worsened over time to the point that he developed a catatonic state. Electroencephalogram revealed no seizures. Supportive care did not improve his cognitive symptoms. However, following the administration of IVIG, his mentation improved, though waxed and waned; he became partially oriented, started talking, and followed simple commands. MRI brain showed resolution of bitemporal hyperintensities.

Current research showed mixed interpretations of the role of IVIG use in N-WNAD. Both clinical and preclinical studies have alluded to a possible beneficial role for IVIG treatment. However, a small phase-II randomized trial failed to establish a benefit from IVIG treatment.

Our observation is in-line with other clinical reports of successful use of IVIG in the treatment of N-WNAD. This calls for further multi-center studies to identify characteristics of patients who may benefit from this treatment.

Authors/Disclosures
Allison N. Block, DO
PRESENTER
Dr. Block has nothing to disclose.
No disclosure on file
No disclosure on file
No disclosure on file
No disclosure on file
Ahmed Z. Obeidat, MD, PhD (Medical College of Wisconsin) Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Alexion. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Biogen . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Bristol Myers Squibb. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for Genentech. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for EMD Serono. Dr. Obeidat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Sanofi/Genzyme . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Horizon pharmaceuticals . Dr. Obeidat has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Sandoz. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for TG Therapeutics. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Biogen. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Bristol Myers Squibb. Dr. Obeidat has received personal compensation in the range of $100,000-$499,999 for serving on a Speakers Bureau for EMD Serono. Dr. Obeidat has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Banner life sciences . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Sanofi/genzyme. Dr. Obeidat has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Horizon therapeutics . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Amgen. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for TG Therapeutics . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for AstraZeneca. The institution of Dr. Obeidat has received research support from NIH. The institution of Dr. Obeidat has received research support from NMSS and PCORI. Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Expert opinion and key opinion leader with MJH life sciences . Dr. Obeidat has received personal compensation in the range of $10,000-$49,999 for serving as a Faculty Speaker with CMSC. Dr. Obeidat has a non-compensated relationship as a Board member with CMSC that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Obeidat has a non-compensated relationship as a Editorial Board Member with IJMSC that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Obeidat has a non-compensated relationship as a Reviewer Editor with Frontiers Neurology that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities. Dr. Obeidat has a non-compensated relationship as a Board of Trustee Member with National MS Society that is relevant to Âé¶¹´«Ã½Ó³»­ interests or activities.